Fri, Dec 10, 2021
The research, published in The New England Journal of Medicine on Thursday, included data from participants 50 years of age or older who had received two doses of Pfizer vaccine at least five months earlier.
More >
Mon, Jan 08, 2018
Pfizer is not making any changes to research and development funding for tanezumab, which is marketed as a treatment for joint pain from osteoarthritis, fibromyalgia treatment Lyrica, or its rare disease program.
By accepting cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
